Terns PharmaceuticalsNASDAQ: TERN

Terns Pharmaceuticals, Inc. (TERN) outperforms the industry year to date on encouraging pipeline progress of its oncology candidate.

The consensus price target hints at a 136.4% upside potential for Terns Pharmaceuticals (TERN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

FOSTER CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in the following upcoming investor conferences in June.

Mizuho analysts believe that Terns Pharmaceuticals Inc.'s stock could experience a significant increase if their oral weight-loss drug performs well in an upcoming early-stage trial data release.

Terns Pharmaceuticals stock is down 15% in the past 10 months, despite bullish articles following a bearish prediction. The company initially planned to develop drugs for the Chinese market but switched to developing US drugs for US consumers. Terns' lead candidate TERN-501, a THR-β agonist, lacks convincing data and faces competition in the NASH market.

TERN's TERN-701 is being developed for Chronic Myeloid Leukemia (CML), but NVS' Scemblix is similar and already approved. TERN-701 may offer benefits to Scemblix, some of which could become apparent as early as this year with some data from a partner's phase 1 trial. TERN's TERN-501 is set to produce data in Q3'23 from a phase 2a trial  in nonalcoholic steatohepatitis (NASH).

FOSTER CITY, Calif., June 06, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity, today announced that management will be participating in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13, 2023 at 8:40 a.m. PT.

Terns Pharmaceuticals has a promising pipeline with potential best-in-class therapies for obesity and NASH. Upcoming data readouts for TERN-601 and TERN-501 could unlock value, with positive outcomes expected for both binary events. Terns is well-financed with cash runway into 2026, and I believe now is the ideal time to build a position.

Does Terns Pharmaceuticals, Inc. (TERN) have what it takes to be a top stock pick for momentum investors? Let's find out.